Alto Neuroscience Q2 2026: $27.6M Net Loss, CFO Adopts 10b5-1 Plan
ANRO has more than doubled off its 52-week low of $3.02.
Summary
Alto Neuroscience's Q2 2026 10-Q shows a widening net loss to $27.6 million, a strong cash position of $244.2 million, and a new CFO 10b5-1 trading plan.
Key Events · Earnings and Guidance · ANRO
-
Q2 Net Loss Widens to $27.6M
Net loss increased 56% year-over-year from $17.7M to $27.6M, driven by a $9.0M increase in R&D expenses, primarily for the ALTO-207 Phase 2b trial.
-
Cash Runway Extended
Cash and equivalents totaled $244.2M at June 30, 2026, plus $94.6M net proceeds from the July 2026 offering, funding operations for at least 12 months.
-
CFO Adopts 10b5-1 Trading Plan
CFO Nicholas Smith adopted a Rule 10b5-1 plan on June 30, 2026 to sell up to 134,886 shares over the next year, subject to price thresholds.
-
Securities Class Action Dismissed
On August 7, 2026, the court granted the company's motion to dismiss the IPO-related securities class action, with plaintiffs granted leave to file a third amended complaint.
Analysis · ANRO · Life Sciences
Alto Neuroscience reported a $27.6 million net loss for Q2 2026, up from $17.7 million a year earlier, driven by a 68% jump in R&D spending as the company advances its ALTO-207 program. The company ended the quarter with $244.2 million in cash and raised an additional $94.6 million in July, extending its runway. Separately, CFO Nicholas Smith adopted a Rule 10b5-1 trading plan for up to 134,886 shares, a routine but notable insider sale arrangement. The securities class action was dismissed on August 7, 2026, though plaintiffs may amend.
At the time of this filing, ANRO was trading at $28.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $3.02 to $29.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.